NASDAQ:CLLS - Cellectis Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$28.14 -0.30 (-1.05 %)
(As of 08/16/2018 01:06 AM ET)
Previous Close$28.44
Today's Range$27.71 - $28.23
52-Week Range$21.70 - $38.85
Volume74,678 shs
Average Volume223,146 shs
Market Capitalization$1.17 billion
P/E Ratio-10.10
Dividend YieldN/A
Beta1.85
Cellectis logoCellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Debt-to-Equity RatioN/A
Current Ratio12.49
Quick Ratio12.48

Price-To-Earnings

Trailing P/E Ratio-10.10
Forward P/E Ratio-13.09
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.72 million
Price / Sales34.72
Cash FlowN/A
Price / CashN/A
Book Value$7.96 per share
Price / Book3.54

Profitability

EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-281.38%
Return on Equity-25.46%
Return on Assets-22.34%

Miscellaneous

Employees135
Outstanding Shares41,600,000
Market Cap$1.17 billion

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.62) by $0.45. The biotechnology company had revenue of $8.34 million for the quarter, compared to the consensus estimate of $9.43 million. Cellectis had a negative net margin of 281.38% and a negative return on equity of 25.46%. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

7 brokers have issued twelve-month price targets for Cellectis' shares. Their predictions range from $20.00 to $73.00. On average, they expect Cellectis' stock price to reach $45.6667 in the next year. This suggests a possible upside of 62.3% from the stock's current price. View Analyst Price Targets for Cellectis.

What is the consensus analysts' recommendation for Cellectis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

Who are some of Cellectis' key competitors?

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 53)
  • Dr. David J. D. Sourdive, Co-Founder, Exec. VP - Technical Operations and Director (Age 51)
  • Mr. Eric Dutang, Chief Financial Officer (Age 44)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 36)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Has Cellectis been receiving favorable news coverage?

Media coverage about CLLS stock has been trending somewhat negative on Wednesday, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cellectis earned a media and rumor sentiment score of -0.06 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 47.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Cellectis.

Who are Cellectis' major shareholders?

Cellectis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (10.19%), Nexthera Capital LP (1.32%), BlackRock Inc. (1.07%), ARK Investment Management LLC (0.59%), Laurion Capital Management LP (0.48%) and Millennium Management LLC (0.35%).

Which institutional investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including Advisors Asset Management Inc. and Jane Street Group LLC.

Which institutional investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Nexthera Capital LP, Laurion Capital Management LP, ARK Investment Management LLC, Aquilo Capital Management LLC, Millennium Management LLC and JBF Capital Inc..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $28.14.

How big of a company is Cellectis?

Cellectis has a market capitalization of $1.17 billion and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 135 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (NASDAQ CLLS)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.